PT  - JOURNAL ARTICLE
AU  - Deneuve, Sophie
AU  - Fervers, Béatrice
AU  - Senkin, Sergey
AU  - Bouaoun, Liacine
AU  - Pérol, Olivia
AU  - Chavanel, Bérénice
AU  - Lu, Lingeng
AU  - Coste, Isabelle
AU  - Renno, Toufic
AU  - Zavadil, Jiri
AU  - Virard, François
TI  - Molecular landscapes of oral cancers of unknown etiology
AID  - 10.1101/2023.12.15.23299866
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.15.23299866
4099  - http://medrxiv.org/content/early/2023/12/17/2023.12.15.23299866.1.short
4100  - http://medrxiv.org/content/early/2023/12/17/2023.12.15.23299866.1.full
AB  - The incidence of the mobile tongue cancer in young patients has been rising. This oral cancer (OC) type has no identified risk factors (NIRF), no established molecular markers and is not yet recognized as a distinct clinical entity.To understand this emerging malignancy, we innovatively analyzed the public head and neck cancer multi-omics data. We identified mutational signatures that successfully stratified 307 OC and 109 laryngeal cancer cases according to their clinico-pathological characteristics. The NIRF OCs exhibited significantly increased activities of endogenous clock-like and APOBEC-associated mutagenesis, alongside specific cancer driver gene mutations, distinct methylome patterns and prominent antimicrobial transcriptomic responses. Furthermore, we show that mutational signature SBS16 in OCs reflects the combined effects of alcohol drinking and tobacco smoking.Our study characterizes the unique disease histories and molecular programs of the NIRF OCs revealing that this emerging cancer subtype is likely driven by increased endogenous mutagenesis correlated with responses to microbial insults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://portal.gdc.cancer.gov/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors